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Rachel Kobos, Peter G. Steinherz, Nancy A. Kernan, Susan E. Prockop, Andromachi Scaradavou,
Trudy N. Small, Neerav Shukla, Ramzi Khalaf, Richard J. O’Reilly, Farid BouladThe development of treatment-related myelodysplastic syndrome (tMDS) or treatment-related acute myelo-
genous leukemia (tAML) is a complication that can occur after chemotherapy or radiation therapy. Eighteen pa-
tients with a previous malignancy treated at our institution and three patients with a nonmalignant primary
tumor received an allogeneic hematopoietic stem cell transplant (HSCT) on the pediatric bone marrow (BM)
transplantation service for the treatment of tMDS/tAML over a 15-year period. Five patients proceeded to
HSCTwithout induction chemotherapy. Fourteen patients received high-dose cytarabine according to the Cap-
izzi II regimen as first-line induction therapy with 13 of them achieving complete remission (CR) or refractory
anemia (RA) with persistent cytogenetic abnormalities after this treatment. Two patients received an
anthracycline-based induction therapy. Conditioning regimens were selected according to previous therapies:
11 patients received busulfan-melphalan-fludarabine (BU-MEL-FLU), which consisted of busulfan (0.8 mg/kg/
dose every 6 hours 10 doses), melphalan (70 mg/m2/dose  two doses), and fludarabine (25 mg/m2/dose
 five doses) for cytoreduction; three patients received a total body irradiation (TBI)-containing regimen; seven
patients receivedmyeloablative regimens containing busulfan and/ormelphalan and/or thiotepawithdosesmod-
ified fororgan toxicity. Sixteenpatients receivedT cell-depleted (TCD) grafts; four patients receivedunmodified
grafts; one patient received a double-unit cord blood transplantation (DUCBT).Donors includedHLA-matched
(n 5 9), or mismatched (n 5 3) related donors, or HLA-matched (n 5 4), or mismatched (n 5 4) unrelated
donors, or DUCBT (n 5 1). Disease status at the time of HSCTwas: morphologic and cytogenetic CR (n 5
12); RAwith positive cytogenetics (n5 6); and refractory disease (n5 3).With a median follow-up of 5.9 years
(2.2-15.7 years), the 5-year overall survival (OS) and disease-free survival (DFS) rates for the entire groupwere
61.1%with 12patients alivewithout evidenceof either primary disease or tMDS/tAML. TheOSandDFS rate for
the 11 patients who received the BU-MEL-FLU cytoreduction with TCD grafts was 54.5%. DFS was 65.7% for
patients in RAorCR atHSCT comparedwith 0% for patientswith.5% residual marrowblasts (P5.015).Nine
patients died; the cause of death was relapse of MDS/AML (n5 4) or primary disease (n5 2), graft-versus-host
disease (GVHD; n5 2), and infection (n5 1). Four patients developed grade II to IV acute GVHD. One patient
developed localized chronicGVHD.Our results suggest that the strategyof inductionwith high-dose cytarabine
therapy followed by allogeneic stem cell transplantation improves the overall outcome for patients with tMDS/
tAML. In addition, the use of a TCD transplantation with BU-MEL-FLU as cytoreduction may decrease the tox-
icity of transplantation in heavily pretreated patients without an increase in relapse rate.
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Overall survival (OS) rates for children diagnosed
with a malignancy are now approaching 80% [1]. Dose
reductions and drug exclusions have been accomplished
in certain diseases such as standard-risk acute lympho-
blastic leukemia with excellent results [2]. However,
many pediatric cancers still require dose-intensive
treatments with cytotoxic drugs and radiation.Unfortu-
nately, these treatments increase the patients’ risk for473
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plastic syndrome (tMDS) and treatment-related acute
myeloid leukemia (tAML) have been observed after
various therapies for pediatric malignancies, especially
solid tumor protocols and particularly in patients
with advanced disease stages. Cumulative incidences of
tMDS/tAML ranging from 5% to 11% have been
reported after current standard solid tumor therapies
consisting of high-dose alkylator and topoisomerase II
inhibitor drugs [3-6]. Efforts to reduce the incidence
of tMDS/tAML have been aimed at decreasing
cumulative dosages without sacrificing dose intensity,
resulting in a reduction but not elimination in the
cumulative incidence of tMDS/tAML [7].
Historically, curative options for tMDS/tAML have
been limited; allogeneic hematopoietic stem cell trans-
plant (HSCT) seems to offer the highest probability of
OS. Chemotherapy alone leads to dismal results in this
particular patient population [8-10]. Important variables
affecting the treatment results for tMDS/tAML include
the use of induction chemotherapy, the cytoreduction
plan for HSCT, and the type of graft used. Recently,
the National Marrow Donor Program and Center for
International Bone Marrow Transplant Research
reported the results of HSCT administered to both
pediatric and adult patients as treatment for tMDS/
tAML. OS rates were 37% at 1 year and 22% at 5 years
[11]. These survival rates are comparable to the 35% 3-
year OS rate reported by the European Group for Blood
and Marrow Transplant for a similar patient population
[12]. Single-institution reports on pediatric patients with
tMDS/tAML in recent years are consistent with these
observations [10,13,14]. Herein, we report the results of
21 patients who received an HSCT for treatment of
tMDS/tAML at Memorial Sloan-Kettering Cancer
Center (MSKCC) under the care of the pediatric bone
marrow transplantation team over a 15-year period.PATIENTS AND METHODS
The MSKCC transplantation database was re-
viewed to identify patients who received an HSCT
for tMDS/tAML under the care of the pediatric bone
marrow transplantation service from October 1994
to October 2009. A waiver of authorization to conduct
this retrospective review was approved by theMSKCC
Institutional Review Board.
Patient Characteristics
Wedescribe herein the results of HSCT for tMDS/
tAML in 21 patients over a 15-year period at MSKCC.
We identified 18 patients who received an HSCT for
treatment of tMDS/tAML after initial treatment at
MSKCC for their primary malignancy. Three addi-
tional patients with nonmalignant primary tumors
received an HSCT at MSKCC for tMDS/tAML andare included in this review. Themedian age at presenta-
tion of primary diseasewas 14 years (range, 3months-26
years). The median age at the time of HSCT was 21
years (range, 8-29 years). Patients who were treated by
the Department of Pediatrics at MSKCC for their first
malignancy were primarily referred to the pediatric
HSCT service, accounting for the 11 patients who
were older than 21 years of age. Themedian time to de-
velopmentof tMDS/tAMLafter thediagnosisof thepri-
mary malignancy was 3.42 years (range, 1.1-16.4 years.)
The median time to development of tMDS/tAML after
the last treatment for primary disease was 1.32 years
(range, 0.13-11.4 years). Additional characteristics of
these 21 patients including gender, primary disease,
treatment of primary disease, and stage at diagnosis of
tMDS/tAML are detailed in Table 1.
Cytogenetics
Using karyotype and fluorescent in situ hybridiza-
tion studies, nine diagnostic leukemia samples were
found to have a single chromosomal abnormality,
nine samples had multiple cytogenetic abnormalities,
and the remaining three samples had no aberrations de-
tected. Themost frequent chromosomal abnormalities
involved translocations of 11q23 (n 5 8). The partner
chromosomes were chromosome 9 (n 5 2), chromo-
some 19 (n 5 2), chromosome 4 (n 5 1), and in three
patients, the partner chromosome was not identified.
One additional patient had a documented 11q23 rear-
rangement on a diagnostic sample but not on subse-
quent samples with overt leukemia. Six patients had
abnormalities of chromosome 7, four patients had ab-
normalities of chromosome 5, and three patients had
trisomy 8. The other abnormalities that were noted
either as a single event or in combination with the
above-mentionedmutations were:monosomy 2; t(2;9);
trisomy 6; t(6;11)(p21.3; p15); deletion 9q; deletion
13q; t(14;19); monosomy 17; and deletion 20q. To
our knowledge, translocations of (2;9) and t(14;19)
have not previously been described in either de novo
or tMDS/tAML. None of our patients had favorable
cytogenetics. Molecular abnormalities observed in de
novo AML, such as NPM1, CEBPA, KIT, and FLT-3
were not examined routinely in these patients.
Induction Chemotherapy
The time intervals between diagnosis of tMDS/
tAML and treatment were as follows: 19 patients re-
ceived therapy—either induction chemotherapy fol-
lowed by HSCT (n 5 14) or HSCT (n 5 5) within 6
months of diagnosis of tMDS/tAML. One patient
who developed chronic myelomonocytic leukemia
(CMML) after treatment for neuroblastoma (NB) was
observed for 3 years until the blast percentage started
to increase.Hewas then treated with induction chemo-
therapy followed by an HSCT. Another patient
Table 1. Patients’ Characteristics
No. of patients 21
Age at diagnosis of tMDS/tAML
Median 21 y
Range 8-29 y
Male/female 10/11
Primary diagnosis
Osteosarcoma / Neuroblastoma / Ewing Sarcoma 5/3/3
Rhabdomyosarcoma / Hodgkin Lymphoma / other malignancy 2/1/4
Nonmalignant (thalassemia, SLE, Polyarteritis Nodosa) 3
Treatment of primary malignancy
TBI (400-1500 cGy) 4
Cyclophosphamide IV (3600-26,300 mg/m2) 14
Cyclophosphamide oral (5400 mg/m2) 1
Daunorubicin (535 mg/m2) 1
Doxorubicin (150-460 mg/m2) 17
Etoposide IV (1200-4800 mg/m2) 13
Etoposide oral (4200-6300 mg/m2) 1
Ifosfamide (22,500-160,000 mg/m2) 8
Relapse of primary malignancy before development
of tMDS/tAML
7
Stage at diagnosis of MDS – AML
RA 4
CMML 1
RAEB1 3
RAEB2 2
AML 11
Cytogenetic abnormalities
MLL rearrangement or deletion 10
Chromosome 7 abnormalities 6
Chromosome 5 abnormalities 4
Chromosome 8 abnormalities 3
Other 9
Normal 3
Chemotherapy before HSCT 16/21
Stage at HSCT
CR1 11
RA 7
RAEB 2
AML 1
HSCT cytoreduction
BU-(10)-MEL-FLU 11
TBI-containing regimens 3
Busulfan (16) melphalan 2
Busulfan (16) fludarabine 1
Busulfan (16) cyclophosphamide 1
Melphalan-fludarabine-thiotepa 2
Melphalan-fludarabine 1
Donors
Matched related 9
Matched unrelated 4
Mismatched related 3
Mismatched unrelated 5
Graft
Unmodified BM/PBSC 4 (3/1)
Unmodified UCB 1
TCD BM/PBSC 16 (2/14)
tMDS indicates treatment-related myelodysplastic syndrome; tAML,
treatment-related acute myelogenous leukemia; SLE, systemic lupus
erythematosus; TBI, total body irradiation; RA, refractory anemia;
CMML, chronic myelomonocytic leukemia; RAEB, refractory anemia with
excess blast; Busulfan (10), ten doses of Busulfan 0.8 mg/kg; Busulfan (16),
16 doses of Busulfan 0.8 mg/kg; MLL, myelomonocytic leukemia; HSCT, he-
matopoietic stem cell transplantation; CR, complete response; BU-MEL-
FLU, busulfan-melphalan-fludarabine; BM, bone marrow; PBSC, peripheral
blood stem cell; UCB, umbilical cord blood; TCD, T cell depleted.
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transplantation for de novo AML. He developed rising
blast percentage 8 months after being diagnosed with
tMDS/tAMLandproceededdirectly toHSCTwithout
induction chemotherapy.Five of the 21 patients (four refractory anemias
[RAs] and one AML) did not receive chemotherapy be-
fore HSCT. Sixteen patients (one CMML, five refrac-
tory anemia with excess blasts [RAEB], and 10 AMLs)
received induction chemotherapy to decrease disease
burden before HSCT. Seven of 16 patients received
one cycle, and nine patients received two to three cycles
of chemotherapy before proceeding to HSCT. Four-
teen patients received frontline induction chemother-
apy with the Capizzi II regimen (high-dose cytarabine
3 grams/m2 every 12 hours4 doses followed by L-as-
paraginase 6000units/m2) [15] either as intensified tim-
ing (given twice, 7 days apart) or as standard timing
(given once) at diagnosis. Thirteen of 14 patients who
receivedCapizzi II as frontline induction chemotherapy
achievedmorphologic remission. Two patients received
an anthracycline-based regimen as a frontline induction,
and only one patient achieved amorphologic remission.
The two patients in whom the initial attempt at in-
duction failedwent on to receive additional chemother-
apy regimens.Onewas treatedwith a clofarabine-based
regimen, which also included topotecan, thiotepa, and
vinorelbine [16] after failing one of the above-
mentioned regimens (Table 2).
Transplantation Characteristics
HLA typing was performed using sequence-
specific oligonucleotide probe testing methods for
the following antigens: HLA-A, HLA-B, HLA-C,
DRB1, and DQB1. Donors were HLA-matched sib-
lings (n 5 9), matched unrelated donors (n 5 4),
mismatched related donors (n5 3), mismatched unre-
lated donors (n5 4), or mismatched unrelated double-
unit cord blood transplant (DUCBT; n 5 2). The
seven patients who received HLA-mismatched grafts
had varying degrees of mismatch (7-9/10 antigen
match); three patients had a class I antigen mismatch,
while the remaining four patients had class II antigen
mismatches. The patient who received a DUCBT
was HLA matched at 4 and 6/10 antigens.
Transplantation conditioning regimens varied based
on donor availability, the patient’s condition, and prior
exposure to radiation-limiting total body irradiation
(TBI) as an option. Eleven patients received the same
conditioning regimen consisting of busulfan-melphalan-
fludarabine (BU-MEL-FLU) and are the focus of this
article. This regimen consisted of busulfan dosed at 0.8
mg/k dose for 10 doses (n 5 9) or 12 doses (n 5 2) on
days -9 to -7, melphalan 70 mg/m2/dose  two doses on
days -7 and -6, fludarabine 25 mg/m2/dose  five doses
ondays -6 to -2, and rabbit anti-thymocyteglobulin (Thy-
moglobulin, Genzyme Transplant, Cambridge, MA) at
2.5 mg/k two doses on days -3 and -2.
Six regimens were used for the remaining patients
and are summarized in Table 2. Three patients re-
ceived regimens of TBI combined with fludarabine.
Two patients received melphalan, fludarabine, and
Table 2. Patient, Donor, and Graft Characteristics
Primary
Disease
Age
(y)/Sex at
Primary
Disease
Time from
Primary to
tMDS/tAML
(y)
Age
HSCT
(y)
Stage at
Diagnosis
Induction
Chemotherapy
Stage at
HSCT Cytoreduction Donor Grafts Outcome
Time
Post-HSCT
(mo)
1 OS 13/F 1.8 16 RAEB Capizzi II CR BU-MEL-FLU 8/10 rel TCD-PB A 40+
2 ES 5/F 4.6 10 RAEB Capizzi II RA BU-MEL-FLU Match rel TCD-PB A 53+
3 HD 14/F 1.4 17 RAEB Capizzi II CR BU-MEL-FLU 8/10 URD TCD-PB A 92+
4 ES 24/M 4.4 29 AML Capizzi II CR BU-MEL-FLU Match URD TCD-PB A 71+
5 NB 3 mo/M 7 8 AML Capizzi II CR BU-MEL-FLU 8/10 URD TCD-PB A 36+
6 OS 19/F 5 25 AML Capizzi II RA BU-MEL-FLU Match rel TCD-PB D-infection 2
7 OS 16/F 4.4 22 AML Capizzi II CR BU-MEL-FLU 9/10 URD TCD-PB D-GVHD 20
8 RMS 17/M 2.2 20 AML Capizzi II CR BU-MEL-FLU 8/10 rel TCD-PB D-secondary 10
9 MFH 16/F 4.6 22 AML Capizzi II failed
DCTER failed
TVTC-PR
RAEB BU-MEL-FLU Match rel TCD-PB D-secondary 5
10 Thal 1/M 22.4 23 RA N/A RA BU-MEL-FLU Match rel TCD-PB A 106+
11 RMS 16/M 9.7 27 AML DCTER failed
Capizzi II
RA BU-MEL-FLU 7/10 rel TCD-PB D-secondary 7
12 DSRCT 12/M 2.5 15 RAEB Capizzi II CR MEL-FLU-THIO Match rel TCD-PB A 58+
13 SLE 9/F 8.4 17 RA N/A RA MEL-FLU-THIO Match URD TCD-BM D-GVHD 8
14 PN 10/M 15.6 27 AML Ida-AraC X 3 CR TBI-FLU Match rel TCD-BM A 138+
15 AML 4/M 16 21 AML N/A AML TBI-THIO-FLU Match URD TCD-PB D-secondary 7
16 OS 26/F 1.4 29 AML Capizzi II CR TBI-CY-FLU DUCBT D-primary 53
17 NB 3/M 1.4 9 CMML Capizzi II RA BU-MEL Match rel BM A 52+
18 ES 21/F 1.3 23 RAEB Capizzi II CR BU-MEL 9/10 URD BM A 116+
19 NHL 16/M 6.7 23 RA N/A RA BU-CY Match rel BM A 198+
20 NB 23/F 2.1 26 RA N/A RAEB BU-FLU Match rel TCD-PB D-primary 88
21 OS 12/F 1.1 14 AML Capizzi II CR MEL-FLU Match URD PB A 94+
tMDS indicates treatment-related myelodysplastic syndrome; tAML, treatment-related acute myelogenous leukemia; HSCT, hematopoietic stem cell
transplantation; OS, osteosarcoma; F, female; RAEB, refractory anemia with excess blasts; CR, complete remission (blasts <5% with normal cytogenet-
ics); BU, busulfan; MEL, melphalan; FLU, fludarabine; Rel, related; TCD, T cell-depleted transplantation; PB, peripheral blood stem cell graft; A, alive; ES,
Ewing sarcoma; RA, refractory anemia (blasts <5% but persistence of abnormal cytogenetics); Match rel, HLA-matched related donor; HD, Hodgkin
lymphoma; URD, unrelated donor; M, male; AML, acute myelogenous leukemia; NB, neuroblastoma; D-infection, died from infection; D-GVHD, died
from graft-versus-host disease complications; RMS, rhabdomyosarcoma; D-secondary, died from relapsed tMDS/tAML; MFH, malignant fibrous histio-
cytoma; DCTER, daunorubicin, cytarabine, thioguanine, etoposide, dexamethasone; TVTC, thiotepa, vinorelbine, topotecan, and clofarabine [16]; PR,
partial response, reduction in blast percentage in the bone marrow to <20%; Thal, thalassemia; N/A, not applicable; DSRCT, desmoplastic small round
cell tumor; THIO, thiotepa; SLE, systemic lupus erythematosus; BM, bone marrow graft; PN, polyarteritis nodosa; Ida-AraC, idarubicin with cytarabine;
TBI, total body irradiation; CY, cyclophosphamide; DUCBT, double-unit cord blood transplantation; D-primary, died from relapsed primary disease;
CMML, chronic myelomonocytic leukemia; NHL, Non-Hodgkin lymphoma.
476 Biol Blood Marrow Transplant 18:473-492, 2012R. Kobos et al.thiotepa as cytoreduction; two patients received busul-
fan and melphalan [17], and three patients received in-
dividualized transplantation regimens (Table 2).
Sixteen patients received T cell-depleted (TCD)
transplantations of which 14 were peripheral blood
stem cell (PBSC) and two were bone marrow (BM)
grafts. Using the ISOLEX 300i Magnetic Cell Selec-
tion System, CD341 cells were positively selected fol-
lowed by sRBC-rosette depletion of T cells [18] in
PBSC grafts. TCD was accomplished in BM grafts
by sequential soybean lectin agglutination and
sRBC-rosette depletion (SBA-E) [19].
Patients who received TCD grafts from unrelated
donors also received equine or rabbit anti-thymocyte
globulin, depending on the protocol, to prevent graft
rejection and further reduce the risk of graft-versus-
host disease (GVHD).
Four patients received unmodified grafts (two were
PBSC and two were BM). One patient received
a DUCBT. These patients received either tacrolimus
and methotrexate or cyclosporine and mycophenolate
mofetil for GVHD prophylaxis.
GVHD was diagnosed clinically; a biopsy was per-
formed when possible. Patients were evaluable foracute GVHD once engrafted and .30 days from
HSCT. An acute GVHD score was given based on
Center for International BoneMarrowTransplant Re-
search criteria [20]. Chronic GVHD was evaluated in
patients who survived at least 100 days using the Sulli-
van scoring criteria [21].
Engraftment was defined as ANC$500/uL for$3
consecutive days and platelets $20,000/uL without
transfusion for$7 consecutive days. Donor chimerism
was performed on BM aspirates to confirm engraft-
ment status.
Statistics
Kaplan-Meier analysis was used to determine OS
and disease-free survival (DFS). DFS was defined as
the interval from transplantation to death or relapse
of tMDS/tAML. Differences in survival between
groups were tested using the log-rank test.RESULTS
All 21 patients engrafted. The results of HSCT for
these patients are displayed in Figure 1A. Twelve pa-
tients are alive and in remission of both primary and
Figure 1. (A) Five-year overall survival (OS) and disease-free survival
(DFS) rates for 21 patients with hematopoietic stem cell transplantation
(HSCT) with treatment-related myelodysplastic syndrome (tMDS) and
treatment-related acute myelogenous leukemia (tAML). Disease-free
status represents patients who have not relapsed with tMDS/tAML.
One patient did relapsewith Ewing sarcoma afterHSCT.Hewas salvaged
with chemotherapy and is alivewithout evidence of either disease for.2
years. (B) Impact of disease status at time of HSCTonOS rates. Eighteen
patients had#5% blasts in the bonemarrow at the time of HSCTwith an
OS of 65.7% compared with a 0% OS for the three patients who pro-
ceeded to HSCTwith.5% blasts in the bone marrow (P 5 .015).
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HSCT (median, 6.8 years). The 5-year OS rate from
the date of HSCT was 61.1%. Nine patients have
died. The causes of death were relapse of tMDS/
tAML (n 5 4), relapse of primary disease (n 5 2),
GVHD (n 5 2), and infection (n 5 1). The relapse
rate of tMDS/tAML was 19%, with an average time
to relapse of 5.5 months (range, 4-6 months). All four
patientswho relapsedwith tMDS/tAMLdied fromdis-
ease within 10months fromHSCT. Two patients died
from a relapse of their primary malignancy (osteosar-
coma and neuroblastoma) at 52 and 88 months post-
HSCT, respectively, without evidence of tMDS/
tAML at the time of death. One patient relapsed with
Ewing sarcoma 2 years post-HSCT but was treated
with salvage chemotherapy and is in complete remis-
sion (CR) for both diseases at 3 years after relapse.
Three patients (14%) died from treatment-related
mortality (TRM). Two of these deaths were related to
GVHD and occurred at 8 and 22 months post-
transplantation, respectively. The third patient
developed significant infectious complications post-
transplantation, including a pulmonary aspergilloma,
and died 54 days after HSCT.
Four patients (19%) developed grade II to IV acute
GVHD after HSCT. Two of these patients received
TCD HLA-matched grafts, one received a TCD 9/
10HLA-mismatched graft, and one received a conven-
tional 9/10 HLA-mismatched graft. Two of these four
patients died from infectious complications.6months
from transplantation, likely related to immunosuppres-
sive treatments for GVHD.The third patient, who had
skin and gastrointestinal GVHD, died from relapsed
tMDS/tAML. The fourth patient had regression of
gastrointestinal GVHD and remains in remission of
both malignancies at 8 years posttransplantation.
Chronic GVHD occurred in one patient who de-
veloped limited skin involvement after an unmodified
matched sibling BM transplant, which has resolved.
The strongest predictor for OS was the stage of dis-
ease at the time of HSCT (Figure 1B). At the time of
HSCT, 12 patientswere inCR, six were inRAwith pos-
itive cytogenetics, two were staged RAEB, and one had
AML. The OS for the 18 patients with CR or RA at
the timeofHSCTis 65.7% (P5 .015). All three patients
who proceeded to HSCT with.5% blasts in their BM
have died.Using cytogenetic abnormalities as aminimal
residual disease (MRD)marker, we observed a favorable
outcome if cytogenetics had normalized at the time of
HSCT. Patients who proceeded to transplantation
with negative MRD had a 50%OS (n5 9), while those
patients with detectable disease had a 37% OS (n 5 9;
P 5 0.586). Three patients had normal cytogenetics at
diagnosis, and, therefore, cytogenetic analysis could
not be used to evaluate MRD.
The significance of specific cytogenetic abnormal-
ities could not be assessed in this limited series.However, the majority of the patients (86%) had mu-
tations usually associated with poor prognosis.
Patients younger than 21 years of age had a higher
OS compared with those $21 years of age (78% vs
40%; P 5 .178), but, given the limited size of the
cohort, the difference was not significant.
To analyze the impact of the therapy preceding
tMDS/tAML on outcome, we compared patients who
had a relapse of their primary malignancy requiring
multiple regimens of chemotherapy before tMDS/
tAML with those patients who only received one regi-
men before developing tMDS/tAML.There was a trend
toward improved outcome in patients receiving less ini-
tial therapy, as OS was 54% for the nonrelapsed group
(n5 11) and 43% for the relapsed group (n5 7;P5 .44).
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tMDS/tAML did not influence outcome. The nine pa-
tients who developed tMDS/tAML within 4 years of
diagnosis of their primary malignancy had a slightly
higher OS rate (57%) than the 12 patients who had
a later presentation of tMDS/tAML (50%), but the
increase was not significant (P 5 .274).
Fourteen patients received the Capizzi II regimen
as a first-attempt induction regimen. Thirteen of these
patients achieved an RA or CR status, nine of whom
(64%) are alive and disease-free posttransplantation.
The one patient who did not achieve a response con-
tinued with disease despite two additional induction
attempts. She then proceeded to HSCT in an RAEB
status and relapsed early posttransplantation.
Eleven patients received a TCD graft after BU-
MEL-FLU (as described previously). The OS for this
subset of patients is 54.5%. Six patients are alive with-
out evidence of disease and engraftment status is 100%
donor at 1 year posttransplantation. All but one patient
was 100% donor at day 30 posttransplantation; one pa-
tient was 95% donor at day 30 and converted to and re-
mained 100% donor by 1 year posttransplantation.
Five patients died within a year from transplantation
and were not evaluable for chimerism status at 1 year.
Three patients died from relapsed tMDS/tAML, one
patient died from GVHD, and one patient died from
infection acutely posttransplantation.
Eight patients received Capizzi II as an induction
regimen followed by BU-MEL-FLU as a transplanta-
tion preparative regimen with five patients alive and
disease free (63%). Three patients who received this
combination of therapy died from infection (n 5 1),
GVHD (n 5 1), and relapse of tMDS/tAML (n 5 1).DISCUSSION
Therapy-related MDS/AML is a devastating com-
plication after cytotoxic therapy in pediatric patients,
and reported experiences of treatment attempts have
been discouraging. Hijiya et al. [22] reported in 2009
a 5-year survival of 23% for children diagnosed with
tAML during the period of 1995 to 2003 from the Sur-
veillance, Epidemiology, and End Results. Recent sin-
gle-institution reports from the Hospital for Sick
Children and University of Texas MD Anderson de-
scribed 5-year OS rates of 20% and 14%, respectively
[10,13]. The St. Jude’s Children’s Research Hospital
reported a 3-year OS of 13.7% in their review [14].
Sample number, diagnoses, and follow-up time were
similar to ours in these three reports. The St. Jude’s
experience included the highest number of patients
(n 5 38). We observed a higher than expected 5-year
OS rate of a 61.1% for 21 patients receiving an HSCT
as treatment for tMDS/tAML over a 15-year period.
Although this is a retrospective review that is limited
based on small patient numbers and single-institutionanalysis, these results are encouraging. Our experience
included three patients with nonmalignant primary dis-
eases; removing these patients from our analysis still
yields a higher than expected 5-year OS of 60%.
Two recent comprehensive reports of tMDS/
tAML, including both adult and pediatric patients,
provide a broader description of the expected survival
in this population. Litzow et al. used data from the
Center for International Bone Marrow Transplant
Research to evaluate the effect of HSCT on survival of
patients with tMDS/tAML. The 1-year OS was 37%,
and the 5-year OS was 22% for the 868 patients
reviewed from 1990 to 2004. Kroger et al. [12] re-
ported on a similar population of patients using the
European Group for Blood and Marrow Transplant
data and found a 3-year OS of 35% for 461 patients.
Both studies identified poor disease control at the
time of HSCT to be a contributing factor to poor out-
comes [11,12]. These findings highlight the importance
of successful remission induction chemotherapy.
Most studies of tMDS/tAML have used various in-
duction regimens for patients before HSCT, which in-
cludes anthracyclines, etoposide, and lower dosages of
cytarabine [10,13]. We observed successful remission
induction rates with high-dose cytarabine.Themajority
of patients in this review (86%) proceeded to HSCT in
CRorRA, whichmay have contributed to the improved
DFS.Thirteenpatientswith.5%ofblastswent into re-
mission after Capizzi II dosing of cytarabine. Although
high-dose cytarabine is associated with a high incidence
of infectious morbidity even in de novo AML [23, 24],
we observed tolerable infectious complications, none
of which impeded progression to HSCT. In fact, nine
of the 14 patients who received Capizzi II as up front
therapy are alive and disease free.
Eighteen of 21 patients (86%) in this review had
unfavorable cytogenetic abnormalities that have been
correlated with poor outcome in various studies. The
remaining three patients had normal karyotypes with
negative fluorescent in situ hybridization markers.
Although most of the abnormalities observed were
consistently described as high-risk features, some of
the chromosomal changes in our patients have ambig-
uous prognostic significance in the literature. These
included deletion of 9q, 20q, or translocations involv-
ing 11p15 [25-27]. An important observation is that,
despite the majority of patients having a high-risk cy-
togenetic profile, the DFS and OS in this report
were still superior to those in the literature [25,27].
A major contributing factor to the poor rate of sur-
vival of this population is treatment-related morbidity
and mortality. Patients who develop secondary malig-
nancies are at risk for organ toxicity during HSCT
because they have received high doses of cytotoxic ther-
apy before HSCT. The majority of patients included in
this review were exposed to high-dose chemotherapy
and radiation and, in fact, three patients had undergone
Biol Blood Marrow Transplant 18:473-492, 2012 479Allogeneic Hematopoietic Stem Cell Transplantationprior HSCTs. Seven patients experienced a relapse of
their primary malignancy necessitating further cycles
of chemotherapy before diagnosis and treatment of
tMDS/tAML. Despite this heavily pretreated popula-
tion, the TRMwas only 14%. Amajor factor associated
with this decreased toxicity is the use ofTCD transplan-
tations leading to a reduction of GVHD and the lack of
toxicity from GVHD chemoprophylaxis medications.
Only four of our patients (19%) developed acute grade
II to IVGVHD, and one developed chronicGVHDde-
spite the use of HLA-mismatched donors in nine of 22
patients. The concern for increased relapse rates in pa-
tients with MDS/AML treated with TCD transplanta-
tions has been raised in the medical literature. As
described previously, however, the results of TCD
transplantations from our institution for MDS or
AML have been associated with a relapse rate compara-
ble to that of unmodified transplantations [28]. More-
over, in this high-risk population, we found an
incidence of relapse of 19%, which is lower than that
previously described in the literature [10,13,14]. In
addition, we found the preparative regimen of BU-
MEL-FLU to be tolerable without significant toxicity
in this heavily pretreated population. There were only
two instances of treatment-related mortality among
the 11 patients who received this regimen; one patient
died fromGVHD, and one patient died from infection.
Our results support previous findings that alloge-
neic HSCT offers a curative option for patients who
develop tMDS/tAML after cytotoxic therapy. We re-
port in this series a higher than expected OS and
DFS of 61.1%, albeit these are limited by sample
size, single-institutional experience, and multiple
treatment approaches. Nonetheless, our data suggest
that the strategy of induction with high-dose cytara-
bine-based chemotherapy offers the best chance of
achieving minimal disease before HSCT, which is
a strong predictor of DFS after HSCT. In addition,
a TCD allogeneic HSCT using BU-MEL-FLU as
the cytoreduction approach has been associated with
improved outcome in this very high-risk population.ACKNOWLEDGMENTS
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Lymphodepleting Chemotherapy and Donor
Lymphocyte Infusion for Relapsed Hematologic
Malignancies Postallogeneic Hematopoietic
Cell Transplantation
Erica D. Warlick, Todd DeFor, Bruce R. Blazar, Linda Burns,
Michael R. Verneris, Celalettin Ustun, Daniel J. Weisdorf, Jeffrey S. MillerFew therapeutic strategies exist for hematologic malignancies relapsing post allogeneic hematopoietic cell
transplantation. We present outcomes on 35 patients with nonchronic myelogenous leukemia (CML) hema-
tologic malignancies, the majority having acute myelogenous leukemia (AML) or myelodysplastic syndromes/
myeloproliferative disorders (MDS/MPD) (n 5 22) receiving lymphodepleting chemotherapy followed by
donor lymphocyte infusion (DLI) at 2 T cell dose levels (0.5 and 1.0  108 CD3/kg). Forty-nine percent of
patients achieved complete remission (CR), with a median duration of remission of 6 months (range:
2-711). CR rates were similar between the 2 groups. The incidence of acute graft-versus-host disease
(aGVHD) of any grade was 49%. We saw a higher incidence of grade II-IV aGVHD, with a rate of 66% using
the higher-dose DLI (grade III, 33% and grade 4, 20%) versus only 25% (10% grade III-IV) with the lower-dose
DLI (P5.06).Overall survival at 1 and 2 yearswas 30% (95% confidence interval [CI], 16%-45%) and 19% (95%
CI, 8%-34%); however, for those achievingCR, 1- and 2-year survival was improved at 44% (95%CI, 20%-66%)
and 28% (95% CI, 8%-52%) (P5.03), respectively. These results demonstrate that DLI after lymphodepleting
chemotherapy for relapsed hematologic malignancies results in frequent CRs. The lower DLI dose regimen
improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD.
Biol Blood Marrow Transplant 18: 480-486 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Lymphodepleting chemotherapy, Relapse, Allogeneic cell transplantation, Donor lymphocyte
infusion, DLIINTRODUCTION
Relapse of underlying hematologicmalignancy fol-
lowing allogeneic hematopoietic cell transplant (HCT)
remains a major obstacle for long-term disease-free
survival [1]. Therapeutic options for patients relapsing
with nonchronic myelogenous leukemia (CML) dis-
ease post allogeneic HCT are limited and often unsuc-
cessful. The literature describing responses to donor
lymphocyte infusion (DLI) post allogeneicHCTvaries
